Has COVID impacted the way you consider using subcutaneous pertuzumab/trastuzumab in treatment of HER2+ breast cancer?  


Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice